M. Zeba Baktiyar, B. Mohammed Ishaq, Siva Sanker Reddy L, M. Sreenivasulu
M. Zeba Baktiyar, B. Mohammed Ishaq*, Siva Sanker Reddy L, M. Sreenivasulu
Department of Pharmaceutical Analysis, Santhiram College of Pharmacy, Nandyal, Kurnool, Dist. A.P. India. 518501.
Volume - 14,
Issue - 6,
Year - 2021
A simple, precise and reproducible RP-HPLC method was developed for the estimation of related substances in tilorone dihydrochloride. Quantification was performed using a Zorbax SB-phenyl column (150 × 4.6mm, 5µ) with mobile phase A: 20mM potassium dihydro phosphate + 2ml of triethylamine, pH 2.30 and mobile phase B: acetonitrile, methanol and water 60: 20: 20% v/v. A gradient program was followed with a run time of 55 minutes at a flow rate of 1.0 ml/min. The column temperature was maintained at 40°C, the injection volume was 10 µl and the detection was performed at 269nm using a PDA detector. The retention time of Tilorone dihydrochloride was found to be 10.36 minutes. The proposed method has been validated according to the ICH guidelines for Linearity, Precision, Accuracy, LOD, and LOQ. The method was linear from 0.157 - 3.934µg/ml for standard, 0.153-3.820µg/ml and 0.166 - 4.140µg/ml for impurities, TLHC01 and TLHC02 respectively. The impurities TLHC01 and TLHC02 have been mapped in all stress conditions. The LOD and LOQ of TLHC01 were found at 1.757µg/ml and 5.857µg/ml and 1.919µg/ml and 6.396µg/ml respectively for TLHC02 respectively. Statistical analysis showed that the method was precision, reproducible, selective, specific and accurate for the analysis of Tilorone dihydrochloride and its impurities. The wide range of linearity, sensitivity, precision, short retention times and simple mobile phase have shown that the method is suitable for the routine quantification of mass impurities of tilorone hydrochloride and its dosage pharmaceutical forms with high precision and accuracy.
Cite this article:
M. Zeba Baktiyar, B. Mohammed Ishaq, Siva Sanker Reddy L, M. Sreenivasulu. Method Development and Validation for Estimation of related Substances in Tilorone Dihydrochloride using RP¬-HPLC. Research Journal of Pharmacy and Technology. 2021; 14(6):3319-4. doi: 10.52711/0974-360X.2021.00577
M. Zeba Baktiyar, B. Mohammed Ishaq, Siva Sanker Reddy L, M. Sreenivasulu. Method Development and Validation for Estimation of related Substances in Tilorone Dihydrochloride using RP¬-HPLC. Research Journal of Pharmacy and Technology. 2021; 14(6):3319-4. doi: 10.52711/0974-360X.2021.00577 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-6-67
1. Akira M. High-resolution CT in the evaluation of occupational and environmental disease. Radiol Clin North Am. 2002; 40(1): 43-59.
2. Papachristou G, Papachristou DJ, Schoedel K, Mc Grath K, Slivka A. Systemic silicosis that involves the pancreas. Gastrointest Endosc. 2006; 63(1): 170-2.
3. Stark P1, Jacobson F, Shaffer K. Standard imaging in silicosis and coal worker's pneumoconiosis. Radiol Clin North Am. 1992; 30(6): 1147-54.
4. Marchiori E1, Ferreira A, Saez F, Gabetto JM, Souza AS Jr, Escuissato DL, Gasparetto EL. Conglomerated masses of silicosis in sandblasters: high-resolution CT findings. Eur J Radiol. 2006; 59(1): 56-9.
5. Xian Ming Zeng, Gary Peter Martin Christopher Marriott. The controlled delivery of drugs to the lung. International Journal of Pharmaceutics. 1995; 124(2, 3): 149-164
6. Stringfellow D, Glasgow L. Tilorone hydrochloride: An oral interferon-inducing agent. Antimicrob Agents Chemother. 1972; 2: 73-8.
7. Registry of Medicinal Products (RLS). Tilorone: Prescribing Information (in Russian). Available from: https://www.fda.gov/ForIndustry/DataStandards/ Substance Registration System-Unique Ingredient Identifi erUNII/. [Last retrieved on 2019 Oct 02].
8. Leont’ev IG. Lavomax in outpatient treatment of urogenital chlamidiasis in males. Urologiia 2007; 5: 60-3.
9. Bredehorn T, Duncker GI. Tilorone-induced functional changes in the rat retina (German). Klin Monatsbl Augenheilkd 2000; 216: 219-22.
10. Prokopek M. The Tilorone-induced mucopolysaccharidosis in rats. Biochemical investigations. Biochem Pharmacol 1991; 42: 2187-91.
11. X. Zhang, L. Yang, S. Zhai, J. Duan. Simultaneous quantification of tiloronoxim and tilorone in human urine by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B, 2008; 875: 349–357.
12. MM. Annapurna, Duvvi Sri Valli. Derivative Spectrophotometric Methods for the Determination of Tilorone - An Antiretroviral Drug. Asian Journal of Pharmaceutics. 2018: 12 (1), S288-S295.
13. ICH Q2 (R1), “Validation of analytical procedures: text and methodology,” in Proceedings of the International Conference on Harmonization, Geneva, Switzerland, 2005; 1–13.
14. ICH, Stability Testing of New Drug Substances and Products. International Conference on Harmonisation, IFPMA, Geneva, 2000; 13.